USPTO Patent Application: NEO-201 Antibody for Suppressing Myeloid Derived Suppressor Cells

ChangeBridge: Patent Apps - Peptides (C07K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083840A1) detailing methods for ablating myeloid derived suppressor cells using the NEO-201 antibody. The application describes the antibody's specific binding to certain O-glycans and its potential use in treating cancers and infectious diseases by suppressing gMDSCs.

View original document View source feed page

What changed

This document is a publication of a United States Patent Application (US20260083840A1) filed by inventors Kwong Y. Tsang, Massimo Fantini, and Philip M. Arlen. The application describes methods for ablating granulocyte myeloid derived suppressor cells (gMDSCs) using an antibody named NEO-201. The antibody specifically targets glycosylated peptides found in CEACAM5 and CEACAM6. The patent application outlines potential therapeutic uses of NEO-201, alone or in combination with other agents, for treating cancers, infectious diseases, and other conditions where gMDSCs suppress innate immunity. It also includes diagnostic and therapeutic methods.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, companies involved in pharmaceutical research, development, and manufacturing, particularly in oncology and infectious diseases, should monitor the progress of this patent application. If granted, it could impact the intellectual property landscape for therapies targeting gMDSCs and related conditions. No specific compliance deadlines or penalties are associated with this publication.

Source document (simplified)

← USPTO Patent Applications

METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY

Application US20260083840A1 Kind: A1 Mar 26, 2026

Inventors

Kwong Y. TSANG, Massimo FANTINI, Philip M. ARLEN

Abstract

NEO-201, an antibody that specifically binds to glycosylated peptides carrying core-1 and/or extended core-1 O-glycans comprised in CEACAM5 and CEAMCAM6 but not to aglycosylated CEACAM5 or aglycosylated CEAMCAM6 surprisingly has been shown to bind to and kill granulocyte myeloid derived suppressor cells (gMDSCs). gMDSCs are known to suppress innate immunity in different cancers and infectious diseases, among other conditions. Based thereon the use of NEO-201 alone or in combination for treating cancers and infectious diseases and other conditions wherein gMDSCs suppress innate immunity against the disease are provided. These methods optionally include detecting gMDSCs before, during or after NEO-201 treatment. Diagnostic methods, therapeutic methods, and combination therapies using NEO-201 optionally in combination with another agent in order to ablate gMDSCs and disease cells are also described.